Good news for cannabis stocks, but European markets down
Cannabis stocks were celebrating this week, on the news that the United Nation’s Commission for Narcotic Drugs voted to reschedule cannabis. This means cannabis is effectively removed from a list including ‘hard’ drugs, such as heroin.
Only one member state rejected the move, however most Western countries, voted in favour of the proposal.
This comes almost two years after the World Health Organisation (WHO) recommended the rescheduling of cannabis and cannabis-related substances.
In general market news, Chris Beauchamp, Chief Market Analyst at IG says, “A slew of dour PMI readings has weighed on sentiment in European trading, while in London Rolls-Royce is enjoying a rebound after news of a new push into narrow-body aircraft.
“A more cautious mood has descended on stock markets in Europe this morning, after final PMI readings provided a less than stellar outlook for the region.
“The rash of figures confirmed the pessimistic near-term view of the eurozone economy and for the UK as well, as service sectors across the continent remain in contraction territory.
“Losses on stock markets are still relatively modest, since like the downturn earlier in the year, today’s figures have very much been a reflection of existing information – everyone can see it will have been tough month thanks to lockdown measures bearing down on economic performance.
“Stock markets continue instead to look for an upside case to support further gains from their current levels, but despite talk of progress on US stimulus, the EU recovery fund and Brexit, nothing as yet has appeared that can really galvanise investors into piling back into equities.
“Rolls-Royce has always managed to demonstrate a capacity to adapt to even the toughest times, and today’s announcement about a move back towards the narrow-body jetliner market has provided the spark the shares have been searching for in order to maintain their rebound from the November lows.
“The shares have only recouped around a third of their losses from late October, and the bounce since the beginning of November is perhaps only the latest in a series of false dawns for a share price that has yet to find a low.”
S&P 500: -0.06%
FTSE 100: + 0.42%
DAX: - 0.45%
CAC 40: - 0.15%
Asia Dow: + 0.54%
Nikkei 225: + 0.03%
Hang Seng: + 0.74%
ASX 200: + 0.38%
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.